Price Alert

Sera Prognostics Inc. (SERA)

NASDAQ: SERA · Real-Time Price · USD

2.25

-0.05 (-2.17%)

At close: Aug 14, 2025, 3:59 PM

2.25

0.00%

After-hours: Aug 14, 2025, 04:04 PM EDT

-2.17% (1D)

Bid	2.13
Market Cap	82.59M
Revenue (ttm)	108K
Net Income (ttm)	-32.73M
EPS (ttm)	-0.85
PE Ratio (ttm)	-2.65
Forward PE	-2.75
Analyst	n/a

Ask	2.88
Volume	61,284
Avg. Volume (20D)	390,351
Open	2.27
Previous Close	2.30
Day's Range	2.21 - 2.31
52-Week Range	1.37 - 9.13
Beta	0.99

About SERA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SERA

Website n/a

Full Company Profile

Earnings Surprise

Sera Prognostics has released their quartely earnings on Aug 6, 2025:

Revenue of $17K misses estimates by $53K, with -29.17% YoY decline.

EPS of -0.16 exceeds estimates by 0.07, with 36.00% YoY growth.

Next Earnings Release

Sera Prognostics Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

-9.44%

Sera Prognostics shares are trading lower after th... Unlock content with Pro Subscription

News

1 week ago · seekingalpha.com

Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript

Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Austin Aerts - Chief Financial Officer Evguenia Lindgardt - President, CEO & Direc...

1 week ago · fool.com

Sera Prognostics (SERA) Q2 Loss Down 4%

Sera Prognostics (SERA 12.24%), a diagnostic company specializing in pregnancy risk prediction, reported Q2 2025 results on August 6, 2025. The company's headline news was a net loss improvement and c...

1 week ago · zacks.com

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.25 per share a year ago.

1 month ago · seekingalpha.com

Sera Prognostics: PreTRM Labor Test Should Represent Advance In Risk Assessment

Sera Prognostics' PreTRM test shows strong clinical utility in reducing neonatal morbidity and NICU admissions, outperforming standard cervical length screening. The company is well-capitalized with $...

2 months ago · zacks.com

After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)

Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r...